Company intelligence
CollPlant
Pioneering Regenerative Medicine
About CollPlant
CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.
Verified activity
Signals from CollPlant
10 published signals
Research & Knowledge
CollPlant researchers bioprinted a human artery using tri-axial extrusion bioprinting, an alginate-gelatin-collagen bioink, and primary human endothelial cells, smooth muscle cells, and adventitial fibroblasts into concentric layers representing the intima, media, and adventitia.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers created a biomaterial using DLP printing and GelMA hydrogels to control heart cell behavior using light.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers noted that cyclic stretching has important implications for tissue-engineered heart valves, where cells must infiltrate and remodel a scaffold while experiencing mechanical forces.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers found that cyclic stretching reduced cell invasion by more than 50% for smooth muscle cells and fibroblasts, and by up to 99% for valvular interstitial cells.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers embedded multicellular spheroids into collagen hydrogels and subjected them to cyclic stretching of 3–10% at 1 Hz for two days.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers volumetrically printed native Type I collagen directly inside an organ-on-chip using a ruthenium/sodium persulfate photocrosslinking system regulated with vitamin C.
Reported by Bowman Bagley
Research & Knowledge
CollPlant recommends using its methacrylated recombinant human type I collagen to generate tunable, soft and stiff hydrogels for tissue engineering applications.
Reported by Bowman Bagley
Research & Knowledge
CollPlant published a study showing that increasing collagen stiffness can make breast cancer cells more invasive, with the team culturing triple-negative breast cancer cells on Type I collagen gels at approximately 150 Pa and 1 kPa.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers 3D bioprinted a collagen-based model of Ewing sarcoma for drug screening using extrusion bioprinting.
Reported by Bowman Bagley
Research & Knowledge
CollPlant researchers created 3D tumor models using hydrogel-based microenvironments to study cancer responses to spatially targeted radiation.
Reported by Bowman Bagley